ARPA Bio
in tune with innovative solutions for early therapeutic intervention...
Transforming Alzheimer's Disease Therapy and Diagnosis:
ARPA Bio offers novel diagnostic and therapeutic solutions, which are uniquely designed to treat or even prevent the progression of Alzheimer's disease. Our patented technology targets early-stage neurotoxic amyloid-beta oligomers, facilitating timely interventions that could halt the progression of this debilitating condition. Our innovative tools ensure that potential oligomer formation is targeted before they lead to severe cognitive decline. ARPA Bio's proprietary targets enable early diagnosis and therapeutic intervention by binding molecular seeds of neurotoxic amyloid-beta oligomers. This is how we prioritize precision and efficacy in treatment options, which are currently not available on the market. ARPA Bio's strategy offers a clear advantage when compared to the current immuno-therapies applied in clinics, because these therapies were designed to typically bind large amyloid oligomers or more mature amyloid morphologies such as protofibrils or fibrils.
Our unique market position and how we aim to revolutionize early therapeutic intervention:
At ARPA Bio, different experts, with a heterogenous scientific background complement the strong R&D team. One of our main discovery and diagnostic tools is mass spectrometry-based proteomics, which we routinely apply for biomarker discovery and quantiation in human CSF and plasma samples.
Transforming Alzheimer's Disease Therapy and Diagnosis:
Our proprietary antibodies enable early diagnosis and therapeutic intervention by binding early seeds of neurotoxic amyloid-beta species. ARPA Bio uses this strategic advantage to develop a proprietary, mass spectrometry-based platform, which allows a limit of detection of multiple biomarkers in the femto-picogram/ml range for future CSF and plasma diagnostics.
